1. Ponikowski P, Voors AA, Anker SD, et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016;37:2129-2200m. 10.1093/eurheartj/ehw128
2. Williams B, Mancia G, Spiering W, et al 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339
3. Rodgers JE, Patterson JH (2001) Angiotensin II-receptor blockers: Clinical relevance and therapeutic role. Am. J. Heal. Pharm. 2001;58:671–683
4. Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническая фармакогенетика: Учебное пособие / Под ред. В.Г. Кукеса, Н.П. Бочкова.- М.:ГЭОТАР Медиа. 2007. [Sychev D.A., Ramenskaya G.V., Ignat'ev I.V., Kukes V.G. Klinicheskaya farmakogenetika: Uchebnoe posobie / Ed by V.G. Kukes, N.P. Bochkova.- M.:GEOTAR Media. 2007 (In Russ).]
5. Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22:366–376. https://doi.org/10.1016/j.drudis.2016.09.015